Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA, USA.
Cancer Biomark. 2010;9(1-6):177-92. doi: 10.3233/CBM-2011-0187.
Breast cancer is the second leading cause of cancer death in women in the United States. While mammography and breast magnetic resonance imaging (MRI) improve detection of early disease, there remains an unmet need for biomarkers for risk stratification, early detection, prediction, and disease prognosis. A number of early breast lesions, from atypical hyperplasias to carcinomas in situ, are associated with an increased risk of developing subsequent invasive breast carcinoma. The recent development of genomic, epigenomic, and proteomic tools for tissue biomarker detection, including array CGH, RNA expression microarrays, and proteomic arrays have identified a number of potential biomarkers that both identify patients at increased risk, as well as provided insights into the pathology of early breast cancer development. This chapter focuses on the detection and application of tissue and serum biomarkers for the identification and risk stratification of early breast cancer lesions.
乳腺癌是美国女性癌症死亡的第二大主要原因。虽然乳房 X 光摄影和乳房磁共振成像(MRI)提高了早期疾病的检出率,但仍需要生物标志物来进行风险分层、早期检测、预测和疾病预后。许多早期的乳腺病变,从非典型增生到原位癌,都与发展为后续浸润性乳腺癌的风险增加有关。基因组学、表观基因组学和蛋白质组学组织生物标志物检测工具的最新发展,包括 array CGH、RNA 表达微阵列和蛋白质组学阵列,已经确定了许多潜在的生物标志物,这些标志物不仅可以识别高风险的患者,还可以深入了解早期乳腺癌发展的病理学。本章重点介绍组织和血清生物标志物的检测及其在早期乳腺癌病变的识别和风险分层中的应用。